Prognostic role of CIP2A expression in serous ovarian cancer

British Journal of Cancer

Volumn 105, Issue 7, 2011, Pages 989-995

  Bockelman C ^a,b   Lassus, H ^a   Hemmes, A ^a,b   Leminen, A ^a   Westermarck, J ^c   Haglund, C ^a   Butzow R ^a,b   Ristimaki A ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

CIP2A; grade; ovarian cancer; prognosis; survival

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER RELAPSE; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROUS OVARIAN CANCER; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT OUTCOME;

AUTOANTIGENS; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053244610     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.346     Document Type: Article

References (30)

1. Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C (2011) High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 104: 1890-1095
2. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15: 5092-5100
3. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH (2010) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18: 857-865
4. Dubeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197
5. Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Bützow R, Ristimäki A (2004) Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10: 538-545 (Pubitemid 38173992)
6. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H, Blomqvist C (1998) Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 78: 1507-1513 (Pubitemid 28517549)
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96 (Pubitemid 351521864)
8. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62 (Pubitemid 47039258)
9. Junttila MR, Westermarck J (2007) Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7: 592-596
10. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662 (Pubitemid 32331572)
11. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101: 793-805
12. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J (2011) ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 6: e17979
13. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232
14. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847 (Pubitemid 28331029)
15. Landen CN, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005 (Pubitemid 351398093)
16. Lassus H, Leminen A, Lundin J, Lehtovirta P, Bützow R (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91: 504-512 (Pubitemid 38388142)
17. Lassus H, Leminen A, Väyrynen A, Cheng G, Gustafsson JA, Isola J, Bützow R (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92: 31-39 (Pubitemid 38147368)
18. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Bützow R (2006) Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84: 671-681 (Pubitemid 44164262)
19. Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214 (Pubitemid 11167383)
21. Mumby M (2007) PP2A: unveiling a reluctant tumor suppressor. Cell 130: 21-24 (Pubitemid 47031327)
22. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108 (Pubitemid 40372904)
23. Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518 (Pubitemid 38529752)
24. Shih I, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11: 7273-7279 (Pubitemid 41507684)
25. Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19: 7-15 (Pubitemid 30010638)
26. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih I (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224 (Pubitemid 40170640)
27. Soo Hoo L, Zhang JY, Chan EK (2002) Cloning and characterization of a novel 90kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 21: 5006-5015
28. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256 (Pubitemid 33104278)
29. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322: 1021-1027 (Pubitemid 20146659)
30. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, Jia J (2010) Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J Med Microbiol 59: 259-265